Skip to main content

Advertisement

Table 3 The detailed subgroup analysis results of clinicopathological parameters

From: Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis

Clinicopathological parameters TILs site Different countries
Any Intratumoural Peritumoral Total Asia Europe/North America
Age > 50 vs. ≤ 50 (OR) 0.867[0.699,1.076]; I2 = 66.3 %; z = 1.30; p = 0.195 0.855[0.562,1.303]; I2 = 89.8 %; z = 0.73; p = 0.466 _ 0.804[0.669,0.965 ]; I2 = 0.0 %; z = 2.35; p = 0.019 1.081[0.894,1.307 ]; I2 = 0.0 % ; z = 0.81 ; p = 0.420 0.731[0.592, 0.901]; I2 = 55.6 %; z = 2.93 ; p = 0.003
Tumour size > 2 cm vs. ≤ 2 cm (OR) 1.151[0.997,1.329]; I2 = 25.0 %; z = 1.92 ; p = 0.055 1.098[0.966,1.247]; I2 = 0.0 %; z = 1.43; p = 0.151 _ 1.268[0.954,1.686 ]; I2 = 37.0 %; z = 1.64 ; p = 0.101 1.296[0.867,1.935 ]; I2 = 54.9 %; z = 1.26 ; p = 0.206 1.146[1.016 , 1.293]; I2 = 0.0 %; z = 2.22; p =0.026
LN(+) vs. LN(−)(OR) 1.305[1.071 ,1.590]; I2 = 60.0 %; z = 2.64; p =0.008 1.121[0.953 ,1.318]; I2 = 38.4 %; z = 1.37; p = 0.169 2.917[1.067 ,7.971]; I2 = .%; z = 2.09; p = 0.037 1.590[1.057 ,2.394]; I2 = 65.9 %; z = 2.22; p = 0.026 1.636[0.993 ,2.693]; I2 = 71.2 % ; z = 1.93; p =0.053 1.209[1.017 ,1.437 ]; I2 = 41.6 %; z = 2.16; p =0.031
pT:T3/T4 vs.T1/T2 (OR) 0.990[0.748 ,1.310]; I2 = 0.0 % ; z = 0.07; p =0.943 0.990[0.748 ,1.310]; I2 = 0.0 % ; z = 0.07; p = 0.943 _ _ _ 0.990[0.748 ,1.310]; I2 = 0.0 % ; z = 0.07; p = 0.943
StageIII/IV vs.I/II (OR) 1.115[0.631 ,1.970 ]; I2 = 68.7 %; z = 0.37; p =0.709 0.925[0.642 ,1.335]; I2 = 30.7 %; z = 0.41; p = 0.679 _ _ 1.181[0.418,3.341 ]; I2 = 79.1 %; z = 0.31; p =0.754 _
Histological grade:III vs.I(OR) 3.769[2.596, 5.472]; I2 = 64.6 %; z = 6.98; p < 0.0001 3.360[1.774, 6.363]; I2 = 79.0 %; z = 3.72; p < 0.0001 _ 4.298[3.221, 5.736]; I2 = 0.0 %; z = 9.88; p < 0.0001 6.248[3.627,10.763]; I2 = .%; z = 6.60; p < 0.0001 3.342[2.270, 4.920]; I2 = 60.0 % ; z = 6.11; p < 0.0001
III vs. II (OR) 2.299[1.719,3.075]; I2 = 80.3 %; z = 5.61; p < 0.0001 1.945[1.551,2.439]; I2 = 56.9 %; z = 5.76; p < 0.0001 _ 3.422[2.706,4.326]; I2 = 0.0 %; z = 10.29; p < 0.0001 2.287[1.740,3.005]; I2 = .%; z = 5.94; p < 0.0001 2.304[1.561, 3.400]; I2 = 85.2 % ; z = 4.20; p < 0.0001
II vs. I (OR) 1.596[1.172,2.174]; I2 = 51.3 %; z = 2.97; p = 0.003 1.790[1.191,2.691]; I2 = 51.2 %; z = 2.80; p = 0.005 _ 1.260[0.947,1.677]; I2 = 18.7 %; z = 1.37; p = 0.171 2.732[1.636,4.562]; I2 = .%; z = 3.84; p < 0.0001 1.351 [1.087, 1.680]; I2 = 0.0 % ; z = 2.64 ; p = 0.008
Lymphatic invasion (+) vs.(−) (OR) 1.382[0.844,2.262]; I2 = 42.8 %; z = 1.29; p = 0.198 _ _ _ 2.071[1.045,4.102]; I2 = 0.0 %; z = 2.09; p = 0.037 _
Vessel invasion (+) vs.(−) (OR) 1.107[0.750,1.634]; I2 = 24.0 %; z = 0.51; p = 0.608 _ _ 1.107[0.750,1.634]; I2 = 24.0 %; z = 0.51; p = 0.608 _ _
ER (+) vs.(−) (OR) 0.435[0.287,0.660]; I2 = 90.3 %; z = 3.91; p < 0.0001 0.571[0.276,1.181]; I2 = 95.7 %; z = 1.51; p = 0.131 _ 0.347[0.252,0.478]; I2 = 31.7 %; z = 6.48; p < 0.0001 0.419[0.193,0.908]; I2 = 88.8 %; z = 2.21; p = 0.027 0.481[0.324,0.714]; I2 = 84.8 %; z = 3.63; p < 0.0001
PR (+) vs.(−) (OR) 0.493[0.296,0.822]; I2 = 89.9 %; z = 2.71; p = 0.007 0.417[0.128,1.357]; I2 = 96.8 %; z = 1.45; p = 0.146 _ 0.501[0.405,0.621]; I2 = 0.0 %; z = 6.31; p < 0.0001 0.432[0.195,0.959]; I2 = 85.1 %; z = 2.06; p = 0.039 0.594[0.373,0.945]; I2 = 79.2 %; z = 2.20; p = 0.028
HER2 (+) vs.(−) (OR) 1.896[1.335,2.692]; I2 = 75.1 %; z = 3.58; p < 0.0001 1.141[0.718,1.814]; I2 = 81.6 %; z = 0.56; p = 0.576 2.299[1.066,4.960]; I2 = .%; z = 2.12; p = 0.034 3.651[2.638,5.052]; I2 = 0.0 %; z = 7.81; p < 0.0001 1.684[0.881,3.218]; I2 = 74.4 %; z = 1.58; p = 0.115 2.059[1.203,3.523]; I2 = 81.0 %; z = 2.64; p = 0.008
Molecular Subtypes :TNBC vs. nTNBC (OR) 2.456[1.801,3.348]; I2 = 11.3 %; z = 5.68; p < 0.0001 3.514[1.563,7.901]; I2 = .%; z = 3.04; p = 0.002 _ 2.342[1.625,3.375]; I2 = 17.5 %; z = 4.57; p < 0.0001 2.990[1.666,5.366]; I2 = 24.6 %; z = 3.67; p < 0.0001 2.230[1.642,3.029]; I2 = .%; z = 5.14; p < 0.0001
Luminal A vs. Luminal B vs. Luminal HER2 vs. HER2-enriched vs. Basal-like _ p < 0.0001 _ p < 0.0001 p < 0.0001 _
  1. OR odds ratio; LN lymph node; ER estrogen receptor; PR progesterone receptor; HER2 human epidermal growth factor receptor-2; TNBC triple-negative breast cancer; “-” no results owing to insufficient studies